Published in Drug Law Weekly, June 13th, 2006
According to recent research from the United States, "Childhood and adolescent AML is traditionally one of the hardest childhood cancers to successfully treat and had all overall survival well under 10% in the 1960s. Initial progress was made by 3 major events: (1) active chemotherapeutic agents were identified which led to remissions for the first time in this disease; (2) cooperative groups were instituted leading to important clinical trials; and (3) several single institutions began experimenting with the role of allogeneic matched sibling donor (MSD) BMT as effective...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.